W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies

News

22 February, 2023
Opinion of the Transparency Council – health policy programme for the municipality of Pszczyna in the field of early detection of colorectal cancer
read more
22 February, 2023
Position of the Transparency Council – Update
read more
22 February, 2023
Position of the Transparency Council – Keytruda (pembrolizumab)
read more
22 February, 2023
Position of the Transparency Council – Glypvilo (vildagliptin)
read more
22 February, 2023
Position of the Transparency Council – Saphnelo (anifrolumab)
read more
22 February, 2023
Opinion of the Transparency Council – amendments to the prenatal testing programme
read more
22 February, 2023
Opinion of the Transparency Council – health policy programme for the of the Municipality of Miękinia on vaccination against meningococcus type B
read more
22 February, 2023
Opinion of the Transparency Council – health policy programme of the Opolskie Voivodeship to support the diagnosis and treatment of infertility
read more
22 February, 2023
Opinion of the Transparency Council – lenalidomide
read more
22 February, 2023
Position of the Transparency Council – Vimetso (vildagliptin + metformin hydrochloride)
read more
22 February, 2023
Opinion of the Transparency Council – health policy programme of the City of Tychy in the scope of infertility treatment with IVF technique
read more
22 February, 2023
Opinion of the Transparency Council – health policy programme of the Municipality of Sztutowo in the field of health needs and health status
read more
22 February, 2023
Position of the Transparency Council – Xiaflex/Xiapex (collagenase Clostridium histolyticum)
read more
22 February, 2023
Position of the Transparency Councii – Findarts Duo (dutasteride + tamsulosin hydrochloride)
read more
22 February, 2023
Position of the Transparency Council – Kyprolis (carfilzomib)
read more
22 February, 2023
Opinion of the Transparency Council – abiraterone acetate
read more
22 February, 2023
Opinion of the Transparency Council – amendments to the drug programme B.56
read more
22 February, 2023
Opinion of the Transparency Council – trastuzumab
read more
22 February, 2023
Opinion of the Transparency Council – amendments to the drug programme B.47
read more
22 February, 2023
Opinion of the Transparency Council – stiripentol
read more
22 February, 2023
Opinion of the Transparency Council – amendments to the drug programme B.90
read more
22 February, 2023
Position of the Transparency Council – Apexxnar
read more
22 February, 2023
Position of the Transparency Councii – Lorviqua (lorlatinib)
read more
22 February, 2023
Opinion of the Transparency Council – venlafaxine
read more

Home page

News Publications Publikacje BIP

#webinar agenda Aktualności announcement of the President azathioprinum Bimzelx Collegium AOTMiT colorectal cancer communication Communication from the Transparency Council Communication on the Tariff Council Cost Accounting Standard Council for Tariffs Affairs covering neonatal care cyclophosphamidum Data acquisition dental treatment services diseases of the organ of vision drug programme Empliciti entecavirum etanercept Fycompa gastroscopy glaucoma health policy program health policy programme health policy programme on breast cancer health policy programme on infertility treatment Health Policy Programmes Impavido in vitro Inovelon Jardiance Meeting of the Transparency Council methotrexatum Milupa Basic-P minimum wage increases mycophenolate mofetil new new tariffs news Notice Notice of the President Ontozry Onureg Opdivo Opdivo (nivolumab)opinion Opinion of the President Opinion of the Transparency Council Ospolot Ozurdex perinatal care Ponvory Position of the Transparency Council Press conference Recommendation Recommendation of the President Renastep report Rezurock sirolimus Suliqua Tariff Council Tariffs Council Tarification Plan 2025 tenofovirum disoproxilum the drug programme B.44 the drug programme B.82 The Meeting of the Tariffs Council trainings Transparency Council Tremfya update Vivitrol Yervoy

Pokaż więcej ↓

Pokaż mniej ↑

Telefon

Page header

News

Opinion of the Transparency Council – health policy programme for the municipality of Pszczyna in the field of early detection of colorectal cancer

Position of the Transparency Council – Update

Position of the Transparency Council – Keytruda (pembrolizumab)

Position of the Transparency Council – Glypvilo (vildagliptin)

Position of the Transparency Council – Saphnelo (anifrolumab)

Opinion of the Transparency Council – amendments to the prenatal testing programme

Opinion of the Transparency Council – health policy programme for the of the Municipality of Miękinia on vaccination against meningococcus type B

Opinion of the Transparency Council – health policy programme of the Opolskie Voivodeship to support the diagnosis and treatment of infertility

Opinion of the Transparency Council – lenalidomide

Position of the Transparency Council – Vimetso (vildagliptin + metformin hydrochloride)

Opinion of the Transparency Council – health policy programme of the City of Tychy in the scope of infertility treatment with IVF technique

Opinion of the Transparency Council – health policy programme of the Municipality of Sztutowo in the field of health needs and health status

Position of the Transparency Council – Xiaflex/Xiapex (collagenase Clostridium histolyticum)

Position of the Transparency Councii – Findarts Duo (dutasteride + tamsulosin hydrochloride)

Position of the Transparency Council – Kyprolis (carfilzomib)

Opinion of the Transparency Council – abiraterone acetate

Opinion of the Transparency Council – amendments to the drug programme B.56

Opinion of the Transparency Council – trastuzumab

Opinion of the Transparency Council – amendments to the drug programme B.47

Opinion of the Transparency Council – stiripentol

Opinion of the Transparency Council – amendments to the drug programme B.90

Position of the Transparency Council – Apexxnar

Position of the Transparency Councii – Lorviqua (lorlatinib)

Opinion of the Transparency Council – venlafaxine